Loading company…
Santo Biopharma develops in vivo gene therapies using lentiviral vector technology.
Santo Biopharma develops gene therapies using its STLenti® 5G lentiviral vector platform, with research focused on oncology conditions including neurofibromas, meningiomas, and malignant mesotheliomas. It also offers consulting and research collaboration services. Founded in 2023 and based in Zhejiang, China, the company raised venture funding from FIRHealth Capital in October 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in